Use of a homozygous G608G progeria mouse model for degenerative joint diseases research
(Beth Israel Deaconess Medical Center) In a study published today in the journal Proceedings of the National Academies of Science, researchers led by Ara Nazarian, PhD, a principal investigator in the Center for Advanced Orthopaedic Studies at BIDMC, investigated the musculoskeletal phenotype of the homozygous G608G BAC-transgenic progeria mouse model, developed at Dr. Collins' lab at the National Institutes of Health, and determined the phenotypic changes of these mice after a five-arm preclinical trial of different treatment combinations with lonafarnib, pravastatin, and zoledronic acid. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 11, 2020 Category: International Medicine & Public Health Source Type: news

UK Oncologist Proposes Novel Treatment for Mesothelioma
Medical oncologist Dr. Angus Dalgleish never did like standard of care treatment for pleural mesothelioma cancer, even when he reluctantly recommended it in the past. He believes now there is something better. Dalgleish, of St. George’s Hospital, University of London, recently published a case report detailing a novel treatment regimen that turned a six-month life expectancy for one patient into a six-year survival. The treatment involved a series of anti-inflammatories that included low-dose naltrexone, vitamin D3 supplements and the vaccine IMM-101, which heightens a patient’s own immune response. “Init...
Source: Asbestos and Mesothelioma News - April 22, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Zoledronic Acid and Neoadjuvant Chemo in HER2- Breast Cancer Zoledronic Acid and Neoadjuvant Chemo in HER2- Breast Cancer
While adjuvant bisphosphonates are associated with longer survival in postmenopausal women with breast cancer, the same cannot be said for neoadjuvant bisphosphonates.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 24, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Denosumab Increasingly Used in Myeloma Despite High Cost Denosumab Increasingly Used in Myeloma Despite High Cost
Denosumab has captured 40% of the market share in just over a year despite a lack of superiority with zoledronic acid and a much higher price tag.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 18, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Zoledronic Acid Reduces Periodontal Disease in Osteoporosis Patients Zoledronic Acid Reduces Periodontal Disease in Osteoporosis Patients
Once-yearly zoledronic acid helps prevent symptomatic periodontal disease in osteoporosis patients, according to industry-funded research.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 27, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Cancer Bone Mets Therapy: One in 40 Patients at Risk for ONJ Cancer Bone Mets Therapy: One in 40 Patients at Risk for ONJ
Clinicians should be aware of near-fivefold raised risk for osteonecrosis of the jaw (ONJ) if zoledronic acid is used to prevent cancer bone metastases, warn researchers.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 5, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Time to Update & quot;Routine, Repeated & quot; Use of Bone Metastasis Drugs Time to Update & quot;Routine, Repeated & quot; Use of Bone Metastasis Drugs
Dr Mark Kris discusses the use of zoledronic acid and denosumab for preventing problems brought on by bone metastases.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 2, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Class 4 medicine defect information: zoledronic acid 5mg solution for infusion
Ranbaxy (UK) Ltd a Sun Pharmaceutical Company, has informed the MHRA that some packs from a batch of zoledronic acid 5mg solution for infusion contain a patient information leaflet for temozolomide 18 (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - April 4, 2019 Category: Drugs & Pharmacology Source Type: news

Zoledronic Acid (Zometa) Injection (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - October 30, 2018 Category: Drugs & Pharmacology Source Type: news

Zoledronic acid improves disease-free survival in premenopausal HR+ early breast cancer
(European Society for Medical Oncology) Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive (HR+) early breast cancer, according to results reported at ESMO 2018 Congress in Munich. It is the first study to assess this specific combination in premenopausal breast cancer and adds to previous observations with zoledronic acid and anastrozole in premenopausal women receiving ovarian suppression. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 22, 2018 Category: Cancer & Oncology Source Type: news

Zoledronic Acid Superior to ART-switching for Low Bone Density in HIV Zoledronic Acid Superior to ART-switching for Low Bone Density in HIV
Zoledronic acid improves low bone mineral density (BMD) better than switching from tenofovir disoproxil fumarate (TDF) to another antiretroviral drug in adults with HIV, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 18, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Acute Phase Reactions After Zoledronic Acid Infusion Acute Phase Reactions After Zoledronic Acid Infusion
Might previous treatment with oral amino-bisphosphonates and higher 25(OH)D levels be protective factors for acute phase reaction to zoledronic acid infusion?Endocrine Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 17, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Zoledronic Acid Prevents Bone Loss in Premenopausal Breast-Cancer Patients Zoledronic Acid Prevents Bone Loss in Premenopausal Breast-Cancer Patients
Zoledronic acid can prevent treatment-related bone loss in premenopausal breast-cancer patients, and the benefit persists for up to three years after treatment, according to new findings.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 26, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Zoledronic acid has no effect on knee pain or bone marrow lesions in knee OA after two years
(European League Against Rheumatism) The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) show that a one-yearly infusion of zoledronic acid (ZA) did not significantly reduce knee pain or bone marrow lesion (BML) size overall in knee osteoarthritis patients over two years. However, it may have symptomatic benefit in milder disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 15, 2018 Category: International Medicine & Public Health Source Type: news

Osteoporosis drug could be used to treat aggressive form of breast cancer, researchers say
(Rockefeller University Press) Researchers in China have discovered that an enzyme called UGT8 drives the progression of basal-like breast cancer, an aggressive form of the disease that is largely untreatable. But the study, which will be published May 4 in the Journal of Experimental Medicine, reveals that the widely used osteoporosis drug zoledronic acid inhibits UGT8 and prevents the spread of basal-like breast cancer in mice, suggesting that this drug could also be used to treat the disease in humans. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 4, 2018 Category: Cancer & Oncology Source Type: news

In Central America, New Adherence Promoters Keep HIV Clients on Treatment
March 02, 2018Carlos considered dropping out of everything. Then he met Aracely, an adherence promoter.Carlos* remembers the exact date he found out he was HIV-positive. He was 20 years old.“January 20, 2015. I was walking with some friends and, over in the square, we saw a tent where they were giving HIV tests,” he says. “As a group of nursing assistants, we said, ‘Let’s do this! Why not?’”Carlos sat alone as he waited for his results. He was #45 in the queue that day.“When they told me I needed additional tests because my results were reactive to virus, I felt my world fall...
Source: IntraHealth International - March 2, 2018 Category: International Medicine & Public Health Authors: cbales Source Type: news

Results From Phase 3 XGEVA ® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology
In this study, XGEVA successfully met the primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to first on-study skeleta... (Source: Amgen News Release)
Source: Amgen News Release - February 9, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

PHARMAC expands funding for zoledronic acid
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2018 Category: Drugs & Pharmacology Source Type: news

An international consortium identifies the breast cancer patients who would benefit from a treatment
(Institute for Research in Biomedicine (IRB Barcelona)) This new knowledge may be key to the early detection of patients who would benefit from zoledronic acid and those who should be spared, and it may accelerate the administration of the first preventive treatment of metastasis. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 19, 2017 Category: Biology Source Type: news

Generic vs Brand Bone Drug for Breast Cancer, Skeletal Mets Generic vs Brand Bone Drug for Breast Cancer, Skeletal Mets
Monthly denosumab more effective than zoledronic acid in delaying time to first skeletal-related events but over 2 years cost almost $350K more.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 18, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Bone Health Drug Inhibits Mesothelioma Tumor Growth
A drug used to treat bone disease and high blood calcium levels may carry benefits as part of a combination treatment for malignant pleural mesothelioma, a recent study concluded. Researchers at the University of Alabama at Birmingham Comprehensive Cancer Center conducted a pilot study testing the effects of zoledronic acid — a bisphosphonate, or bone health drug, marketed as Reclast and Zometa — against a small group of patients with unresectable pleural mesothelioma. The study, published in the June edition of Lung Cancer: Targets and Therapy journal, was a follow-up to preclinical research showing zoledron...
Source: Asbestos and Mesothelioma News - July 20, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: bone disease treatment keytruda mesothelioma treatments Muhammad Omer Jamil reclast treating malignant pleural mesothelioma University of Alabama at Birmingham Comprehensive Cancer Center Zoledronic acid zometa Source Type: news

New Evidence Points to Benefits of Zoledronic Acid for Advanced...
The bisphosphonate may be an option for mesothelioma patients who are not benefitting from other treatments.(PRWeb July 01, 2017)Read the full story at http://www.prweb.com/releases/2017/07/prweb14478826.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 1, 2017 Category: Pharmaceuticals Source Type: news

Denosumab Shows Benefits in Multiple Myeloma Bone Disease Denosumab Shows Benefits in Multiple Myeloma Bone Disease
In a head-to-head comparison with zoledronic acid, denosumab was noninferior, with prolonged time to a first skeletal event and a reduced risk for renal events.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 27, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Amgen To Present New Data At 22nd Congress of the European Hematology Association
Oral Presentation of Phase 3 Data Shows KYPROLIS® (Carfilzomib) and Dexamethasone Improved Median Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed Multiple Myeloma New Subset Analysis Demonstrates BLINCYTO® (Blinatumomab) More Than Doubled Median Overall Survival Versus Standard of Care Chemotherapy in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Salvage Oral Presentation of New Data From Head-to-Head Phase 3 Study of XGEVA® (Denosumab) Versus Zoledronic Acid in Time to First On-Study Skeletal...
Source: Amgen News Release - June 21, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Presents New Data From Phase 3 XGEVA ® (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017
Analysis Demonstrated XGEVA had a Significantly Lower Rate of Renal Adverse Events Compared to Zoledronic Acid Data Selected for Best of ASCO® Educational Program THOUSAND OAKS, Calif., June 4, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the XGEVA® (denosumab) Phase 3 '482 study, the largest international multiple myeloma trial ever conducted. The study met its primary endpoint, demonstrating XGEVA is non-inferior to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma (HR=0.98, 95 percent CI: 0.85, 1.14; p=0.01). The ...
Source: Amgen News Release - June 4, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Mylan Launches Generic Reclast(R) Injection
HERTFORDSHIRE, England and PITTSBURGH, June 2, 2017 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Zoledronic Acid Injection, 5 mg/100 mL Single Dose Vial, a generic version of Novartis' Recl... Biopharmaceuticals, Generics, FDA, Product Launch Mylan, Zoledronic Acid, Reclast, Paget's disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 2, 2017 Category: Pharmaceuticals Source Type: news

Amgen Highlights Data To Be Presented At ASCO 2017 Across Oncology Portfolio
Oral Presentation of New Analysis on Limited Renal Toxicity Associated With XGEVA® (denosumab) Compared With Zoledronic Acid in Treatment of Myeloma Bone Disease XGEVA Study in Patients With Myeloma Bone Disease Also Selected for Best of ASCO® First Randomized Study to Evaluate the Combination of IMLYGIC® (talimogene laherparepvec), an Oncolytic Viral Immunotherapy, With a Checkpoint Inhibitor to be Presented THOUSAND OAKS, Calif., May 17, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new clinical data and analyses from across its oncology portfolio will be presented at the 53rd An...
Source: Amgen News Release - May 17, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

ACP Updates Guidelines on Treating Low Bone Density, Osteoporosis (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD Clinicians should offer alendronate, risedronate, zoledronic acid, or denosumab to women with osteoporosis to reduce the risk for hip and vertebral fractures (strong … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 9, 2017 Category: Primary Care Source Type: news

Guideline for treating low bone density or osteoporosis to prevent fractures
The American College of Physicians recommends in an evidence-based clinical practice guideline that physicians treat women with osteoporosis with bisphosphonates (alendronate, risedronate, or zoledronic acid) or denosumab, a biologic agent. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 9, 2017 Category: Science Source Type: news

Amgen Presents New Data From Phase 3 XGEVA ® (denosumab) Study In Multiple Myeloma Patients At The 16th International Myeloma Workshop
In this study, XGEVA® (denosumab) met the primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to first on-study skeletal-related event (SRE) in patients with multiple myeloma (HR=0.98, 95 percent CI: 0.85, 1.... (Source: Amgen News Release)
Source: Amgen News Release - March 3, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present New KYPROLIS ® (Carfilzomib) And XGEVA® (Denosumab) Data At The 16th International Myeloma Workshop
Detailed Results From Phase 3 Head-to-Head ENDEAVOR Trial Show KYPROLIS Significantly Improved Overall Survival Compared to Velcade® (Bortezomib) in Relapsed or Refractory Multiple Myeloma Patients Late-Breaking Results From Largest International Trial Conducted in Multiple Myeloma Show XGEVA was Non-Inferior Versus Zoledronic Acid in Delaying Bone Complications THOUSAND OAKS, Calif., March 1, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from the KYPROLIS® (carfilzomib) and XGEVA® (denosumab) clinical development programs will be presented at the 16th International Myeloma ...
Source: Amgen News Release - March 1, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

New clinical trial to test drug combination to treat osteogenesis imperfecta
The University of Edinburgh will conduct a six-year trial of teriparatide and zoledronic acid combination to treat a condition called osteogenesis imperfecta (OI). (Source: Drug Development Technology)
Source: Drug Development Technology - January 18, 2017 Category: Pharmaceuticals Source Type: news

Reducing Zoledronic Acid Frequency Did Not Raise Risk of Skeletal Events
Among cancer patients with bone metastases, administration of zoledronic acid every 12 weeks did not increase the risk of skeletal events over 2 years compared with the standard dosing of every 4 weeks. (Source: CancerNetwork)
Source: CancerNetwork - January 6, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bone Metastases Breast Cancer Multiple Myeloma News Prostate Cancer Source Type: news

Powerful Drug for Advanced Cancers May Need Less Frequent Dosing
Patients whose disease has spread to bone can cut side effects tied to zoledronic acid, researchers report Source: HealthDay Related MedlinePlus Pages: Bone Cancer, Breast Cancer, Prostate Cancer (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - January 4, 2017 Category: Consumer Health News Source Type: news

Powerful Drug for Advanced Cancers May Need Less Frequent Dosing
WEDNESDAY, Jan. 4, 2017 -- Use of a bone cancer drug once every three months, instead of monthly, does not boost the risk of bone problems over two years, a new study finds. That could reduce side effects from the drug, known as zoledronic acid... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 4, 2017 Category: Journals (General) Source Type: news

Powerful Drug for Advanced Cancers May Need Less Frequent Dosing
Patients whose disease has spread to bone can cut side effects tied to zoledronic acid, researchers report (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - January 4, 2017 Category: Cancer & Oncology Source Type: news

Powerful Drug for Advanced Cancers May Need Less Frequent Dosing
Patients whose disease has spread to bone can cut side effects tied to zoledronic acid, researchers report (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 4, 2017 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Family Medicine, Nursing, Oncology, Pharmacy, Rheumatology, News, Source Type: news

Longer Dosing Interval for Zoledronic Acid for Bone Mets Longer Dosing Interval for Zoledronic Acid for Bone Mets
Increasing the dosing interval of zoledronic acid did not cause an increase in skeletal events.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 3, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Docetaxel, zoledronic acid not cost  effective for prostate cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2017 Category: Drugs & Pharmacology Source Type: news

Non-TCA/SSRI Antidepressants Increase Fall Risk in Elderly Frail Women
Antidepressants from classes other than tricyclics (TCAs) and selective serotonin reuptake inhibitors (SSRIs) did not appear to reduce the risk for falls, according to results of the Zoledronic acid in frail Elders to STrengthen bone (ZEST) study. (Source: Caring for the Ages)
Source: Caring for the Ages - September 29, 2016 Category: Health Management Authors: Jason Harris Source Type: news

Make the Diagnosis: Bewildering Bone Pain
(MedPage Today) -- Case Findings: A 23-year-old male presents with a presumed diagnosis of vanishing bone disease (Gorham's disease), a rare condition in which bone is lost in conjunction with an overgrowth of lymphatic vessels. However, the patient presents with ongoing severe pain, which is uncommon in Gorham's disease. He was treated with interferon and zoledronic acid, but discontinued these treatments because of severe side effects. What is your diagnosis? (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 26, 2016 Category: Cardiology Source Type: news

Reclast (zoledronic acid)
Title: Reclast (zoledronic acid)Category: MedicationsCreated: 1/3/2008 12:00:00 AMLast Editorial Review: 9/13/2016 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - September 13, 2016 Category: Rheumatology Source Type: news

Osteoporosis Treatment Alternatives To Bisphosphonates
Big Pharma employs a lot of very serious spin-doctors. I’ll give you a good example. Bisphosphonates For Osteoporosis? A new study just came out on bisphosphonate drugs. These are the most commonly prescribed drugs for osteoporosis. They’re worth about $8.5 billion per year to the drug companies. But this new study says that one-third of the women taking these drugs are still at high risk for fractures.  Now here’s what you have to understand. The study was done by a subsidiary of Merck & Co. They make Fosamax, one of the biggest bone drugs. So instead of saying the drugs don’t work ...
Source: Al Sears, MD Natural Remedies - September 6, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Health Source Type: news